Summary

Sofosbuvir (SOF)has potent activity against hepatitis C virus (HCV). Unpublished studies have also indicated the anti-HCV activity of GS-5816, and the high SVR following a 12-week regimen in noncirrhotic, treatment-naïve HCV patients. These studies spurred the phase 2, open-label, ELECTRON-2 study evaluating the efficacy and safety of an 8-week regimen of SOF + GS-5816 in noncirrhotic, treatment-naïve patients infected with HCV genotype 3, as discussed in this article.